National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cost-effectiveness of golimumab (Simponi®) in the treatment of moderate to severe rheumatoid arthritis.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
20/11/2009 11/05/2010 Reimbursement recommended following price review, June 2010.

The review group did not consider golimumab cost-effective at the submitted price in May 2010.

Following a price reduction the review group now consider golimumab to be cost-effective. June 2010.

Golimumab summary-revised price June 2010